Skip to main content

Biontech Se ADR(BNTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low98.60
Day High102.10
Open:99.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Biontech Se ADR

Select a category then submit the form to load news
Tipranks
BioNTech Expands Oncology Pipeline With New First‑in‑Human BNT3214 Cancer Trial
Tipranks
BioNTech Expands Infectious Disease Pipeline With New Mpox mRNA Vaccine Trial in Africa
Newswire.ca
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Tipranks
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX)
Tipranks
BioNTech’s New HIV Antibody Trial Adds Depth to BNTX’s Long-Term Pipeline Story
Tipranks
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
Tipranks
Morgan Stanley Sticks to Their Buy Rating for BioNTech SE (BNTX)
Zacks Investment Research
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Tipranks
Pfizer and BioNTech Pause modRNA Shingles Ambitions
Zacks Investment Research
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data
Tipranks
BioNTech SE (BNTX) Gets a Buy from Morgan Stanley
Zacks Investment Research
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
Tipranks
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Zacks Investment Research
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
Zacks Investment Research
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
Tipranks
BioNTech Adds Chief People Officer to Management Board to Support Oncology Growth Strategy
Newswire.ca
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
Tipranks
Bank of America Securities Remains a Buy on BioNTech SE (BNTX)
Motley Fool
2 Biotech Stocks Set to Rebound in 2026
Tipranks
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch
Tipranks
BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX
Tipranks
Morgan Stanley Remains a Buy on BioNTech SE (BNTX)
Tipranks
Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
Tipranks
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig
Tipranks
Berenberg Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)
Motley Fool
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month
Tipranks
BioNTech’s BNT142 Trial Termination: What It Means for the Oncology Pipeline and Investors
Zacks Investment Research
What to Expect From Pfizer's Non-Oncology Business in Q4?
What to Expect From Pfizer's Non-Oncology Business in Q4?
Tipranks
BioNTech Outlines 2026 Strategy and Milestones at J.P. Morgan Healthcare Conference
GlobeNewswire
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Tipranks
BioNTech Maps Out Catalyst-Rich 2026 Oncology Agenda at J.P. Morgan Healthcare Conference

Profile

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.